The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 16, 2013
Filed:
May. 30, 2007
Michael L. Hutton, Newton, MA (US);
Matthew Charles Baker, Jacksonville, FL (US);
Jennifer Mae Gass, Atlantic Beach, FL (US);
Rosa Rademakers, Ponte Vedra, FL (US);
Jason Eriksen, Houston, TX (US);
Stuart M. Pickering-brown, Derbyshire, GB;
Ian Reid Alexander Mackenzie, Vancouver, CA;
Howard Feldman, Vancouver, CA;
Samir Kumar-singh, Edegem, BE;
Christine Van Broeckhoven, Edegem, BE;
Marc Cruts, Antwerp, BE;
Ashley Diane Cannon, Jacksonville, FL (US);
Michael L. Hutton, Newton, MA (US);
Matthew Charles Baker, Jacksonville, FL (US);
Jennifer Mae Gass, Atlantic Beach, FL (US);
Rosa Rademakers, Ponte Vedra, FL (US);
Jason Eriksen, Houston, TX (US);
Stuart M. Pickering-Brown, Derbyshire, GB;
Ian Reid Alexander Mackenzie, Vancouver, CA;
Howard Feldman, Vancouver, CA;
Samir Kumar-Singh, Edegem, BE;
Christine Van Broeckhoven, Edegem, BE;
Marc Cruts, Antwerp, BE;
Ashley Diane Cannon, Jacksonville, FL (US);
Mayo Foundation for Medical Education and Research, Rochester, MN (US);
The University of British Columbia, Vancouver, CA;
The University of Manchester, Manchester, GB;
VIB VZW, Zwijnaarde, BE;
Universiteit Antwerpen, Antwerp, BE;
Abstract
This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals.